KOSDAQBiotech & Pharma261200

Dentis

₩2,510▼ 0.40%2026-11-18 close
Market Cap
₩39.7B
Turnover
₩22,098,420
Volume
8.8K
Shares out.
15.8M
PER
—
PBR
0.8×
EPS
-₩533
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit returns, net earnings remain the test

Dentis, a dental implant and medical solutions company, posted operating profit in each quarter from Q1 2026 through Q3 2026, but a net loss attributable to controlling shareholders of KRW 10.4 billion in Q3 2026 leaves the durability of the earnings recovery unconfirmed.

  1. 1

    Operating profit turned positive at KRW 3.06 billion in Q1 2026, then came in at KRW 2.65 billion in Q2 and KRW 1.66 billion in Q3, a declining path.

  2. 2

    For 2025, the company recorded an operating loss of KRW 10.4 billion and a net loss attributable to controlling shareholders of KRW 14.2 billion.

  3. 3

    Annual sales were KRW 114.3 billion in 2024 and KRW 114.2 billion in 2025, flat year on year, and the implant segment accounted for 76.6% of Q1 2026 sales.

  4. 4

    The Q3 2026 net loss attributable to controlling shareholders of KRW 10.4 billion brought the four-quarter total to a net loss of KRW 8.34 billion.

  5. 5

    Debt-to-equity stood at 356.6% at the end of 2025, up from 306.4% in 2022, and operating cash flow was negative in each year from 2023 to 2025.

02

Business structure

Dentis was founded in 2005 and listed on KOSDAQ in 2020 as a dental and medical solutions company. Its core business is dental implants, and it also develops, manufactures and sells medical surgical lights, dental 3D printers and bio products. As of Q1 2026, the implant segment accounted for 76.6% of total sales.

The company expanded its implant lineup with the new AXEL product launched in 2025 and obtained Clean Implant certification. The LUVIS surgical light in its operating room solutions segment is cited as a mid- to long-term growth pillar as global project wins increase.

In digital clear aligner orthodontics, the company obtained FDA certification in 2024, pursued entry into Vietnam, and targets entry into the Japanese market in 2026. Domestically it sells directly, while overseas it sells through dealers and local subsidiaries.

It set up a Smart Clean Factory in 2024 and says it invests more than 6% of annual sales in R&D. Implant production capacity was expanded through a dedicated plant, and a May 2025 securities research report cited total capacity of about KRW 160 billion.

The implant market has many domestic and foreign competitors, so product lineup and overseas distribution networks are seen as core competitive factors.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩26.6B-₩1.6B−5.9%
2025Q4₩22.8B-₩9.6B−42.0%
2026Q1₩30.2B₩3.1B10.1%
2026Q2₩32.1B₩2.6B8.2%
2026Q3₩26.7B₩1.7B6.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩87.1B₩5.6B₩1.2B6.4%4.2%306.4%
2023₩94.3B₩400M₩3.8B0.5%6.9%226.8%
2024₩114.3B-₩400M₩2.9B−0.4%5.3%269.8%
2025₩114.2B-₩10.4B-₩14.2B−9.1%−30.6%356.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual sales were KRW 87.1 billion in 2022, KRW 94.3 billion in 2023 (up 8.3% year on year), KRW 114.3 billion in 2024 (up 21.1%), and KRW 114.2 billion in 2025, unchanged from the prior year. Within 2022 to 2025, 2024 was the largest sales year and 2022 the smallest. Profit moved in the other direction.

Operating profit fell from KRW 5.59 billion in 2022 to KRW 429 million in 2023 (down 92.3%), and turned into an operating loss of KRW 446 million in 2024. The 2025 operating loss widened to KRW 10.4 billion, and the company has posted operating losses for two consecutive years from 2024 to 2025.

Operating margin dropped from 6.4% in 2022 to -9.1% in 2025. Net income attributable to controlling shareholders rose to KRW 3.83 billion in 2023, eased to KRW 2.94 billion in 2024, and in 2025 swung to a net loss of KRW 14.2 billion attributable to controlling shareholders.

Net loss including non-controlling interests was KRW 16.5 billion in 2025. The company attributed 2025 results to bad-debt provisions on receivables, costs for new overseas subsidiaries and marketing, foreign exchange losses, and one-off costs from a subsidiary's accounting-standard transition.

Its separate-basis financials remained profitable, according to the company. In Q1 2026, sales were KRW 30.2 billion (up 32.6% from the prior quarter) and operating profit was KRW 3.06 billion, a swing to profit, while net income attributable to controlling shareholders was KRW 6.36 billion.

Operating profit then declined in Q2 to KRW 2.65 billion (down 13.3% quarter on quarter) and in Q3 to KRW 1.66 billion (down 37.5%), two consecutive quarterly declines.

Q3 2026 sales were KRW 26.7 billion, up 0.5% year on year, yet the company posted a net loss attributable to controlling shareholders of KRW 10.4 billion. Because operating profit and net income attributable to controlling shareholders moved in opposite directions, non-operating items appear to have had a large effect.

05

Industry analysis

The dental implant and digital clear aligner markets are contested by many domestic and foreign companies. In its Q3 2025 results announcement, the company attributed the period's weakness to a weak market combined with temporary costs from setting up an overseas subsidiary.

The company also said marketing costs rose as the clear aligner market expanded. Dentis is broadening from implants into operating room solutions and digital orthodontics. Overseas, expanding distribution through dealers and local subsidiaries is the central task.

The implant lineup competes on the strength of the new AXEL product and Clean Implant certification. How domestic dental demand and overseas hospital project wins feed into results is the key variable for reading the industry cycle.

In the sector, product certification and distribution channels are often cited as differentiating factors. However, comparisons based on public market size or cycle data are limited for now.

06

Outlook

The company said it will treat 2026 as the first year of a return to profitability and firm footing in global markets. It cited cost structure reform, an expanded lineup of global new products and portfolio diversification as drivers of margin improvement.

According to the preliminary consolidated results announced on August 11, 2026, first-half sales were KRW 62.3 billion and operating profit was KRW 5.7 billion, up 697.5% year on year. In the same preliminary release, Q2 sales fell 0.8% year on year, so top-line growth was essentially flat.

Separate-basis operating profit for Q2, confirmed in the semi-annual report, was KRW 4.32 billion, above the consolidated figure of KRW 2.65 billion. The company said it will keep strengthening its high value-added product portfolio and expanding global business in the second half.

The Japan entry for digital clear aligners is targeted for 2026, so progress by year-end is a checkpoint. A May 2025 securities research report projected that completion of Phase 3 Building B would bring implant production capacity to about KRW 200 billion.

How much rising overseas sales feed through to margins alongside lower fixed-cost burdens is the key variable for the outlook.

07

Valuation

PER
—
PBR
0.8×
ROE
-15.8%
EPS
-₩533
BPS
₩3,280
Dividend per share
₩0

Because net losses attributable to controlling shareholders have run through the last four quarters, the price-to-earnings ratio cannot be calculated. With earnings-based multiples unusable, comparison centers on book value. The price-to-book ratio sits below 1x, meaning the share price is below book net assets.

A debt-to-equity ratio of 356.6% at the end of 2025 means the composition of net assets and financial burden must be read together. The company paid no dividends in earlier years, and the current dividend yield is effectively close to zero.

Quarterly earnings swings are large, so the earnings-based reference point also moves from quarter to quarter. The valuation is therefore best read by viewing net asset value and the operating profit trend side by side.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Operating profit recovery

Operating profit turned positive at KRW 3.06 billion in Q1 2026, and the company said consolidated operating margin recovered to 10.1%, back into double digits. Operating profit stayed positive in Q2 and Q3 2026. The company cited cost of sales and SG&A structure improvements as the drivers.

Cost efficiency gains

Q1 2026 consolidated cost of sales was KRW 14.7 billion, down from KRW 17.0 billion a year earlier, and SG&A was KRW 12.5 billion, down about KRW 2.0 billion. According to the semi-annual report, Q2 separate-basis SG&A fell from KRW 8.7 billion to KRW 6.28 billion, a reduction of about KRW 2.4 billion. The higher separate-basis margin was presented as evidence of the profit recovery.

Overseas and medical expansion

The LUVIS operating room solution is cited as a mid- to long-term growth pillar on the back of expanding global project wins. Digital clear aligners target Vietnam after FDA certification and a 2026 entry into Japan. The company also said it will accelerate market share gains for the AXEL implant globally.

09

Bear factors

Continued net losses

The 2025 net loss attributable to controlling shareholders was KRW 14.2 billion and the total net loss was KRW 16.5 billion, with losses widening after the swing to deficit. Q3 2026 brought another swing to a net loss attributable to controlling shareholders of KRW 10.4 billion.

Over the last four quarters that total is a KRW 8.34 billion net loss, so operating profit has not carried through to net profit.

Flat sales and slowing operating profit

Annual sales were flat, moving from KRW 114.3 billion in 2024 to KRW 114.2 billion in 2025. Q3 2026 sales of KRW 26.7 billion rose only 0.5% year on year. Operating profit peaked in Q1 2026 and then declined in Q2 and Q3, two consecutive quarterly declines.

Financial burden and cash flow

At the end of 2025 the debt-to-equity ratio was 356.6% and total liabilities were KRW 163.3 billion. Operating cash flow was -KRW 9.69 billion in 2025, and it was also negative at -KRW 5.36 billion in 2024 and -KRW 9.38 billion in 2023. If reliance on external funding continues, interest and repayment burdens could weigh on earnings.

10

Risk factors

One-off costs and FX

The 2025 results included bad-debt provisions on receivables and foreign exchange losses. Costs for overseas subsidiaries and marketing expansion could make the cost structure volatile in the short term. The company described these as one-off, but the effect of currency moves grows as overseas sales rise.

Debt and funding

Total liabilities were KRW 163.3 billion at the end of 2025 and the debt-to-equity ratio was 356.6%. With operating cash flow negative, overlapping demand from equipment investment and working capital could raise reliance on external funding. Weaker funding conditions could constrain the pace of overseas expansion.

Overseas execution timing

Vietnam and Japan entry for digital clear aligners, and dealer-led expansion overseas, can shift with local certification and contract timing. If target dates slip, the point at which higher overseas sales lift margins also moves later. Share gains for new implant products also depend heavily on distribution partner performance.

11

What to watch next

  1. End of December 2026

    The target year for entering the Japanese market with digital clear aligners. It is the point to confirm whether overseas sales contribution actually grows.

  2. Mid-February 2027 (expected, based on last year's schedule)

    The preliminary full-year 2026 results release. The key questions are whether the operating profit gains from Q1 to Q3 2026 carry through to the full year, and whether controlling-shareholder net earnings recover from the Q3 loss.

  3. By March 31, 2027

    The filing deadline for the 2026 annual report. It will show the size of non-operating items and one-off factors such as bad-debt and FX losses.

  4. Mid-May 2027 (expected, based on the Q1 2026 release timing)

    The Q1 2027 preliminary results release. It will show whether operating margin holds recent levels and whether sales return to year-on-year growth.

  5. Date not set

    Disclosure of Phase 3 Building B completion and updates on AXEL overseas share. It is the point to confirm whether expanded capacity and overseas distribution translate into sales growth.

12

Overall view

Dentis is a dental and medical company that has expanded from implants into operating room solutions and digital clear aligners.

Sales in 2025 stayed at KRW 114.2 billion, in line with 2024, but the operating loss of KRW 10.4 billion and the net loss attributable to controlling shareholders of KRW 14.2 billion widened the deficit.

Operating profit was positive in each quarter from Q1 through Q3 2026, and Q1 consolidated operating margin recovered to 10.1%. However, the Q3 2026 net loss attributable to controlling shareholders of KRW 10.4 billion means net profitability is not yet confirmed.

Strengths include cost and SG&A efficiency and wider overseas clear aligner and medical project wins, while weaknesses include flat sales, a high debt-to-equity ratio and negative operating cash flow.

The price-to-book ratio is below 1x, but no earnings-based multiple is calculated, so valuation depends on reading net assets and earnings trends together. The next checkpoints are the annual profit and loss in the 2026 annual report and Q1 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. hanaw.com
  2. comp.wisereport.co.kr
  3. hankyung.com
  4. m.news.nate.com
  5. v.daum.net
  6. edaily.co.kr
  7. digitaltoday.co.kr
  8. dentis.co.kr
  9. pharm.edaily.co.kr
  10. rapportian.com
  11. dttoday.com
  12. dentalnews.or.kr
  13. dttoday.com
  14. medigatenews.com
  15. comp.wisereport.co.kr
  16. investing.com
  17. dailydental.co.kr
  18. dentalnews.or.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis